GV steps up to back Tillman Gerngross’ new antibody play against Covid-19 — and he’s already thinking about the IPO
Tillman Gerngross had two good reasons to celebrate on Monday.
First, he felt that Pfizer’s upbeat assessment of its pivotal Covid-19 vaccine data marked an unprecedented breakthrough in the speed of vaccine development and a “big day” for science as a whole.
Second, he was ready to offer me a preview of an $80 million round designed to propel his new biotech startup — Adagio Therapeutics — toward an IPO next year as it ramps up what he believes can be a contender for the most powerful antibody available to combat a virus that has repeatedly rattled the globe with waves of rising infection and death rates.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
